Jawahar L. Mehta | Academic Influence

Jawahar L. Mehta's AcademicInfluence.com Rankings

Jawahar L. Mehta

Medical

#3444

World Rank

#3912

Historical Rank

Cardiology

#393

World Rank

#405

Historical Rank

medical Degrees

Jawahar L. Mehta

Philosophy

#11853

World Rank

#16386

Historical Rank

Logic

#8940

World Rank

#11267

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Jawahar L. Mehta's Degrees

Doctorate Medicine University of California, San Francisco
PhD Cardiovascular Medicine University of California, San Francisco

Why Is Jawahar L. Mehta Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jawahar L. Mehta is the Stebbins Chair and Professor of Medicine at the College of Medicine, University of Arkansas for Medical Sciences . Biography Mehta was born in India and migrated to the United States in 1970. He received his M.D. from Punjab University in 1968 and PhD from the University of Uppsala, Uppsala, Sweden. Mehta's thesis topic was "studies on experimental myocardial reperfusion" which he completed under the direction of Prof. Tom Saldeen. He completed his post-graduate training in Medicine at the Mount Sinai Medical Center in New York, followed by a research fellowship at the University of Minnesota, Minneapolis. His first faculty position was at the University of Florida, where he rose to be Professor of Medicine. He was appointed the Stebbins Chair and Professor of Medicine and Director of Cardiovascular Medicine at the College of Medicine, University of Arkansas for Medical Sciences in October 2000. He is currently also an Adjunct Faculty Member at the University of Arkansas, Clinton School of Public Service.

(See a Problem?)

Jawahar L. Mehta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. (1987) (269)
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. (1997) (224)
In Vivo Validation of a Thermodilution Method to Determine Regional Left Ventricular Blood Flow in Patients with Coronary Disease (1978) (199)
Plasma serotonin levels and the platelet serotonin transporter (2007) (151)
Hemodynamic Effects of Labetalol, an Alpha and Beta Adrenergic Blocking Agent, in Hypertensive Subjects (1977) (103)
Effect of Sublingual Nitroglycerin on Regional Flow in Patients With and Without Coronary Disease (1978) (90)
Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. (1992) (77)
Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. (1988) (77)
Left main coronary artery stenosis: clinical spectrum, pathophysiology, and management. (1979) (74)
Platelet function studies in coronary heart disease. IX. Increased platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris. (1980) (69)
Human vascular tissues produce thromboxane as well as prostacyclin. (1983) (61)
Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin. (1978) (61)
Clinical outcome after treatment of rest angina with calcium blockers: comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. (1983) (61)
Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure. (1978) (56)
Regional Coronary Hemodynamic Effects of Ergonovine in Patients with and Without Variant Angina (1980) (56)
Short-term efficacy of oral verapamil in rest angina. A double-blind placebo controlled trial in CCU patients. (1981) (51)
Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis. (1995) (43)
Role of vasoconstrictor mechanisms in the control of left ventricular performance of the normal and damaged heart. (1979) (43)
Reduction in myocardial neutrophil accumulation and infarct size following administration of thromboxane inhibitor U-63,557A. (1987) (40)
Platelet function studies in coronary artery disease. VII. Effect of aspirin and tachycardia stress on aortic and coronary venous blood. (1980) (40)
Superoxide Dismutase Decreases Reperfusion Arrhythmias and Preserves Myocardial Function During Thrombolysis with Tissue Plasminogen Activator (1990) (35)
Mexiletine, a new antiarrhythmic agent, for treatment of premature ventricular complexes. (1982) (34)
Response of rat thoracic aortic rings to thromboxane mimetic U-46,619: roles of endothelium-derived relaxing factor and thromboxane A2 release. (1991) (33)
Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. (1992) (30)
Reduction in blood flow in normal and narrowed coronary arteries of dogs by leukotriene C4. (1985) (29)
Protection of Myocytes From Hypoxia-Reoxygenation Injury by Nitric Oxide Is Mediated by Modulation of Transforming Growth Factor-&bgr;1 (2002) (29)
Superiority of Dobutamine over Dopamine for Augmentation of Cardiac Output in Patients with Chronic Low Output Cardiac Failure (28)
Myocardial damage after repetitive direct current shock in the dog: correlation between left ventricular end-diastolic pressure and extent of myocardial necrosis. (1978) (26)
Increased production of thromboxane A2 by coronary arteries after thrombolysis. (1993) (25)
Effects of exercise-induced oxidative stress on nitric oxide release and antioxidant activity. (1997) (23)
Reperfusion injury in the endotoxin‐treated rat heart: reevaluation of the role of nitric oxide (1997) (21)
Modulation of vascular tone by endothelin‐1: role of preload, endothelial integrity and concentration of endothelin‐1 (1992) (21)
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. (1996) (20)
Haemodynamic effects of hydrallazine and of hydrallazine plus glyceryl trinitrate paste in heart failure. (1978) (20)
A review of the haemodynamic effects of labetalol in man. (1982) (20)
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. (1995) (19)
Protection against ischemia/reperfusion injury and myocardial dysfunction by antisense-oligodeoxynucleotide directed at angiotensin-converting enzyme mRNA (2001) (18)
Attenuation of coronary flow reserve and myocardial function after temporary subtotal coronary artery occlusion and increased myocardial oxygen demand in dogs. (1994) (17)
Effects of Peptide 6A on Coronary Blood Flow Dynamics in Canine Coronary Thrombosis (1989) (16)
Verapamil and aspirin modulate platelet-mediated vasomotion in arterial segments with intact or disrupted endothelium. (1993) (16)
Comparative hemodynamic effects of nitroprusside, prazosin and hydralazine in refractory heart failure (1978) (16)
Effects of prostacyclin on systemic and coronary hemodynamics in the dog. (1981) (16)
Platelet function studies in coronary artery disease. X. Effect of dipyridamole. (1981) (16)
Differences in platelet aggregation in coronary sinus and aortic blood in patients with coronary artery disease: Effect of propranolol (1978) (15)
Aspirin in myocardial ischemia: Why, when, and how much? (1989) (14)
Vasodilators in the treatment of heart failure. (1977) (13)
Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects. (1983) (13)
Adrenergic blockade in hypertension. (1978) (12)
Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. (1983) (12)
Verapamil therapy for unstable angina pectoris: review of double-blind placebo-controlled randomized clinical trials. (1982) (11)
Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects (1998) (11)
302 Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 PUFA intake (1988) (10)
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. (1979) (10)
Acute haemodynamic effects of oral prazosin in severe mitral regurgitation. (1980) (9)
Titrates for treatment of unstable angina pectoris and coronary vasospasm. (1983) (9)
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis. (1991) (9)
Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. (1991) (7)
Non‐parenteral combined afterload and preload reduction therapy in congestive heart failure (1978) (7)
Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs. (1993) (7)
Precipitation of heart failure following sudden withdrawal of hydralazine. (1979) (7)
Long-term oral verapamil therapy in patients with rest angina. (1983) (6)
Long‐term maintenance therapy with prazosin in congestive heart failure (1981) (4)
Effect of L-arginine and an arginine-containing pentapeptide on canine femoral arterial blood flow. (1991) (4)
Combined Thrombolytic Effects of Tissue‐Plasminogen Activator and a Fibrinogen‐Degradation Product Peptide 6A or Iloprost (1991) (4)
Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis. (1996) (4)
Early Hemodynamic Responses to Single Dose Intravenous Nitroglycerin: Time Course Relationships (1981) (3)
Initial medical and surgical management of unstable angina pectoris (1979) (3)
Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. (1997) (2)
Aortic regurgitation associated with ventricular septal defect. Echocardiographic and hemodynamic observations. (1977) (2)
The LOX-1 scavenger receptor and its implication in coronary artery disease (2012) (2)
Dissociation of inotropic from chronotropic effects of isoproterenol during beta blockade with labetalol (Sch 15719W) (1976) (2)
Use of vasodilators in congestive heart failure. (1980) (2)
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. (1992) (1)
Inotropism without chronotropism in response to isoproterenol after combined beta and alpha adrenergic blockade in man (1976) (1)
Modulation of vasoactive prostaglandins by nitro glycerin (1982) (0)
THROMBOLYSIS BY TISSUE-PLASMNOCEN ACTIVATOR AND A FIBRIN (OCEN) -DEGRADATION PRODUCT, PEPTIDE 6A, IN A CANINE MDDEL OF ELECTRICALLY-INDUCED CORONARY THROMBOSIS (1987) (0)
[Usefulness of vasodilators in congestive cardiac insufficiency: studies with prazosin]. (1980) (0)
Long term oral vasodilator therapy in severe right ventricular failure due to right ventricular infarction. (1980) (0)
AS-080 Elevated B-Type Natriuretic Peptide Predicts Contrast Induced Nephropathy in Coronary Interventions (2011) (0)
Effect of propranolol on mortality and morbidity after acute myocardial infarction. (1982) (0)
in hypertensive subjects Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, (2011) (0)
A REVIEW OFTHEHAEMODYNAMIC EFFECTSOFLABETALOL INMAN (1982) (0)
Analytic Review: Treatment of Coronary Artery Spasm and Variant Angina (1986) (0)
Recombinant lys-plasminogen given prior, but not after, tissue-plasminogen activator markedly improves coronary thrombolysis in dogs. (1995) (0)
heart failure . plus glyceryl trinitrate paste in hydrallazine and of hydrallazine Haemodynamic effects of (0)
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. (2023) (0)
Echocardiographic and Hemodynamk Observations (2017) (0)
Comparison ofhaemodynamic effects oforal prazosin, oral hydralazine, andintravenous nitroprusside in samepatients with chronic heart failure' (1979) (0)

This paper list is powered by the following services:

Other Resources About Jawahar L. Mehta

en.wikipedia.org

What Schools Are Affiliated With Jawahar L. Mehta?

Jawahar L. Mehta is affiliated with the following schools:

Image Attributions

Image Source for Jawahar L. Mehta